Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

275 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prostatic penetration of meropenem in humans, and dosage considerations for prostatitis based on a site-specific pharmacokinetic/pharmacodynamic evaluation.
Nishikawa G, Ikawa K, Nakamura K, Yamada Y, Zennami K, Mitsui K, Narushima M, Ikeda K, Morikawa N, Sumitomo M. Nishikawa G, et al. Among authors: narushima m. Int J Antimicrob Agents. 2013 Mar;41(3):267-71. doi: 10.1016/j.ijantimicag.2012.11.001. Epub 2013 Jan 11. Int J Antimicrob Agents. 2013. PMID: 23313536
Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics.
Kobayashi I, Ikawa K, Nakamura K, Nishikawa G, Kajikawa K, Yoshizawa T, Watanabe M, Kato Y, Zennami K, Kanao K, Tobiume M, Yamada Y, Mitsui K, Narushima M, Morikawa N, Sumitomo M. Kobayashi I, et al. Among authors: narushima m. J Infect Chemother. 2015 Aug;21(8):575-80. doi: 10.1016/j.jiac.2015.04.015. Epub 2015 May 14. J Infect Chemother. 2015. PMID: 26050020
Clinical pharmacokinetics and pharmacodynamic target attainment of pazufloxacin in prostate tissue: Dosing considerations for prostatitis.
Nakamura K, Ikawa K, Nishikawa G, Kobayashi I, Narushima M, Muramatsu H, Morinaga S, Kajikawa K, Kato Y, Watanabe M, Zennami K, Kanao K, Morikawa N, Sumitomo M. Nakamura K, et al. Among authors: narushima m. J Infect Chemother. 2017 Dec;23(12):809-813. doi: 10.1016/j.jiac.2017.08.005. Epub 2017 Oct 12. J Infect Chemother. 2017. PMID: 28923301
[Vesicoureteral reflux and urinary incontinence in myelodysplastic patients: a comparison between those who had anti-reflux surgery alone and those who were treated by anti-reflux surgery combined with bladder augmentation with or without sling operation].
Tsuji Y, Saito M, Kondo A, Narushima M, Otani T. Tsuji Y, et al. Among authors: narushima m. Nihon Hinyokika Gakkai Zasshi. 1998 Jan;89(1):43-9. doi: 10.5980/jpnjurol1989.89.43. Nihon Hinyokika Gakkai Zasshi. 1998. PMID: 9493421 Free article. Clinical Trial. Japanese.
275 results